M.L. Gamir

TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.

TL;DR: Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile for infliximab in the treatment of juvenile rheumatoid arthritis, and achievement of the primary efficacy end point at 3 months did not differ significantly between inflIXimab-treated and placebo-treated patients.

TL;DR: In patients with JIA in remission, a 12-month vs 6-month withdrawal of methotrexate did not reduce the relapse rate and low MRP8/14 levels indicated a low risk of flares within the next 3 months following the biomarker test.

TL;DR: To compare the capacity of the 2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis with the capacity for systemic juvenile idiopathic arthritis–associated macrophage activation syndrome to discriminate MAS complicating systemic JIA, two potentially confusable conditions are compared.

TL;DR: The members of PRINTO propose a core set of criteria for the evaluation of response to therapy that is scientifically and clinically relevant and statistically validated and will help standardize the conduct and reporting of clinical trials and assist practitioners in deciding whether a patient with juvenile SLE has responded adequately to therapy.